ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IRON vs AMLX // OPERATING MARGIN

Disc Medicine Inc. (NASDAQ) VS. Amylyx Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: IRON 4 — AMLX 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRON VS. AMLX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IRON AMLX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -27.50% -35.00% +7.50 IRON /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -4.93% -3.43% -1.50 AMLX /fcf-yield <GO>
Operating Margin ACTIVE -22.90% — — TIE /operating-margins <GO>
Net Profit Margin -20.60% — — TIE /net-margins <GO>
Revenue Growth (YoY) 16.50% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 3/9 +2.00 IRON /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 67.0 51.9 +15.11 IRON /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.90 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 20.0x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.68B $3.60B $79.4M IRON /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IRON REV AMLX REV IRON GROSS % AMLX GROSS % IRON FCF AMLX FCF
FY 2025 $0 $0 — — -$181.3M -$123.5M
FY 2024 $0 $87.4M — 93.2% -$94.4M -$167.8M
FY 2023 $0 $380.8M — — -$73.5M $11.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRON // BETA 0.90
AMLX // BETA —